Vote for BJP in urban local bodies" poll for "triple engine" govt in UP: Adityanath
UP: Man booked for attempting to rape 5-year-old girl
Congress to mark 100 days of Bharat Jodo Yatra with concert in Jaipur
BJYM, Hindu outfits put off planned protest march at AMU
Karachi battles gas crisis; residents face unannounced load shedding, 2-hr gas supply in a day
Elderly man in judicial custody dies during treatment in UP hospital
Himachal Pradesh skittle Haryana for 46, take 200-run lead on Day 1
Pak court grants protective bail to PM Shehbaz"s son Suleman in money laundering case
British Library celebrates India ties with exhibition on Hampi
Nine policemen suspended after suspect dies in police custody in UP
Gangster"s property attached in UP"s Pratapgarh district
Maoists torch construction company vehicles in Jharkhand’s Chatra district
Sino-India border situation "generally stable": China on Yangtse clash
Babar Azam not taking advice from seniors, claims Shahid Afridi
Qlite Global launches their exclusive Grand Experience Centre
"Disillusioned with central leadership": Sikkim BJP president says he has resigned
2001 attack anniversary: Ready to guard new Parliament if directed, say CRPF heroes
Class 2 student dies after scuffle with fellow students in UP
Three killed in accident in UP"s Lakhimpur KheriLakhimpur Kheri (UP), Dec 13 (PTI) Three motorcycle borne youths were killed and "
Abandoned girl child from Assam adopted by Spanish professor
Remdesivir, which is manufactured by Gilead Sciences, is the only antiviral currently approved for use against the coronavirus. The US Food and Drug Administration (FDA) gave the drug full approval in October after it was granted emergency use authorization in May last year.
An oral drug for treating COVID-19 could be ready next year, Pfizer CEO Albert Bourla has said. Bourla said that the company is working on two antivirals, an oral and an injectable.
"We are actually on two, one is injectable and the other one an oral (antiviral)... Particularly the attention is on the oral for the world and of us because provides several advantages and one of them is that you don`t need to go to the hospital to get the treatment of which is the case with all the injectables so far but you can get it home," Albert Bourla told CNBC in an interview on Tuesday, as cited by The Hill.
"If all goes well, and we implement the same speed that we are, and if regulators do the same, and they are, I hope that by the end of the year," Bourla added.
Remdesivir, which is manufactured by Gilead Sciences, is the only antiviral currently approved for use against the coronavirus. The US Food and Drug Administration (FDA) gave the drug full approval in October after it was granted emergency use authorization in May last year.
He also said the medication could be "way more effective against the multiple variants" of the virus than current options adding that the mechanism of action, of the antiviral, is not expected to be subject to mutations, "particularly because it`s not acting on the spike, as we all know, all the mutations that we are hearing right now are seeing this in the proteins of the spike."
"This one doesn`t work there so that allows us to believe that will be way more effective against the multiple variants. So, all good news. We are now progressing the studies and we will have more news around summer," the CEO added.
The Hill further reported that thus far, more than 121 million doses of the vaccine have been administered across the United States.
Your support to NYOOOZ will help us to continue create and publish news for and from smaller cities, which also need equal voice as much as citizens living in bigger cities have through mainstream media organizations.
Stay updated with all the Latest Gurgaon headlines here. For more exclusive & live news updates from all around India, stay connected with NYOOOZ.
